This is a momentous time. Finally, here at Healing Oracle we get to report on a fantastic piece of news, something I thought I would never see.
You can all be very proud of yourselves for helping in this fight, for following the updates, for trying GCMAF in the first place and then coming back and testifying to us all how effective this remarkable product really is. It’s down to social justice as well as media, that we can now reveal that the Government finally admits that GCMAF works!
The Trials are in
It would seem the next move would be to manufacture it and we can only hope that one day this will happen. Imagine a time when it is readily available to everyone for free, from the NHS in the UK, to the Insurance listings and Hospitals all over the world? Cancer will decrease and many lives will be saved. This opens up that dream….
In the meantime, you can Purchase GCMAF here
The recently published article proves that doctors, hospitals and government bodies can no longer deny the existence or the effectiveness of GCMAF anymore. The trials are in and the results are in. Below are some exerts from the article:
- Reports have been circulating around the natural health community of a compound known as Gc-protein derived macrophage activating factor, or GcMAF, and its remarkable effects on cancer, Autism and other terminal conditions.
- One of these is a video clip (below) of an in vitro attack of macrophages, a type of immune cell, which have been treated with GcMAF against human breast cancer cells. This can be best described by the common internet meme caption of “nom nom nom,” as the clusters of cancer cells are mercilessly devoured. Fortunately for humans, research on real patients has shown that its effects are not confined to a laboratory.In human patients, however, GcMAF is not administered alone. In this study, GcMAF is described as being complex, the GcMAF is prescribed alongside a vegetarian diet; vitamin D3, omega-3 fatty acids, and fermented products containing naturally-occurring GcMAF.
Although these patients all suffered from advanced cancers, within a few weeks, their tumor volume had decreased by an average of 25%. While some clinical results were compared to chemo in tumor-shrinking power, OA- complexed GcMAF, along with some other types of OA- complexed proteins, destroys cancer cells without any ill effects on healthy cells.
One patient discussed in research is a 56-year-old man suffering from a recurrence of metastatic squamous cell carcinoma that was “successfully” treated with chemo and radiation. Because of his cancer’s location, GcMAF was administered by both a nebulizer and subcutaneous injections. Even after only 5 days of treatment, ultrasonography had shown that his tumors had shrunk by approximately one quarter. He also reported improvement in breathing, with ventilation in the apical right lobe improving.
Another patient was a 62-year-old woman with “extensive” breast cancer and no history of conventional treatment. Within one week, the diameter of the two main lymph metastases (the primary tumor was unable to be measured due to size) shrunk from 3.9 to 3.46cm.
While GcMAF has anti-proliferative, anti-metastatic abilities, oleic acid has its own anticancer properties and may assist in binding to cell membranes. Together, they are 200 times more potent than GcMAF alone in destroying cancer cells in vitro. They also increase levels of nitric oxide, which has anticancer as well as antihypertensive properties.
Other documented cases show similar results. For example, a 63-year-old woman with colon cancer that later spread to her lungs and liver experienced a reduction in her liver tumor from 13 to 6.6mL in only 2 weeks of treatment! This was once again achieved by alternating nebulization and injection of OA-GcMAF.
Another patient was a 43-year old-woman with metastatic breast cancer to the bone and liver. After 1 week of both inhaled OA-GcMAF and that injected into her breast, her primary tumor shrunk from 1.8 to 1.3 mL, which was considered representative of four other cases.
Some are less dramatic, such as that of a man in his 30\s who experienced a reduction in one of his melanoma metastases from 52.1 to 48.6mm.
Overall, the use of GcMAF as a safe treatment alternative looks promising despite frightening stories of opposition. However, more evidence, whether scientific or anecdotal, is needed for a definitive conclusion. This is partly because of the lack of instruction on how to produce anything resembling GcMAF at home (unlike the more well-known cannabis oil), which may either be unfeasible or undesired by those producing it. See links below to purchase or for further information.
Q: Does GcMaf work for HIV?
GcMaf has been very successful with HIV.
To sabotage the immune system and put macrophages to sleep, all viruses make Nagalase, the enzyme that blocks production of GcMAF. Without GcMAF (the protein that activates macrophages and jump-starts the entire immune response) HIV and other viruses can grow unimpeded. Nagalase puts the immune system to sleep. Dr. Nobuto Yamamoto demonstrated that GcMAF administration bypasses the Nagalase blockage and re-activates the macrophages, which then proceed to kill the HIV viruses and cure the infection.
Something to cheer about?
People infected with the Human Immunodeficiency Virus (HIV) have something to get excited about. They just don’t know it yet. In 2009 Dr. Nobuto Yamamoto published a landmark paper entitled: “Immunotherapy of HIV-Infected Patients With Gc Protein-Derived Macrophage Activating Factor (GcMAF)” in the Journal of Medical Virology in which he demonstrated that GcMAF cured 100% of nonanemic HIV infected patients. After seven years of followup, there were no recurrences. All patients maintained healthy CD+ counts. I am experiencing the very same with our patients at the clinic.
Of course, this is just one study. And it had the disadvantage of containing some complex molecular biological chemo-speak. If the reader weren’t familiar with Yamamoto’s decades of background research (all of which was published in journals that HIV researchers and patients wouldn’t be likely to read), this study would fall on deaf ears. But Professor Yamamoto’s HIV study was no quirk. Based on a quarter-century of solid research that predicted success long before the actual human trials, it presented all the science one would need to understand exactly why these HIV patients were cured.
Though this study was published in 2009, there has been no informed discussion on this topic, no further GcMAF research as a therapy for HIV, and no media chatter. It’s as if this study never happened. Why is this?
How GcMAF destroys HIV
HIV—like all viruses—makes Nagalase, the enzyme that blocks GcMAF production. Without GcMAF, macrophages become indolent and the anti-viral immune response shuts down. This allows the HIV infection to spread. To remedy this situation, Dr. Yamamoto simply gave these patients GcMAF. This reactivated the sleeping macrophages, which then proceeded to phagocytize all of the viruses.
The precise molecular biological pathways and mechanisms involved with HIV, Nagalase, and GcMAF are identical to those for cancer cells, and need not be repeated here.
In his HIV study Yamamoto first showed that HIV patients had high Nagalase levels which correlated with their high HIV RNA levels (a way to measure the amount of HIV infection). Then, as he administered GcMAF (100 ng. once a week for 18 weeks), all patients’ Nagalase levels gradually went down to control levels, and, in tandem with the Nagalase, viral load went down to zero. Yamamoto wrote that these data “suggest that these patients were free of both HIV virions and HIV-infected cells.”
Professor Yamamoto followed these patients for seven years, and their viral load (HIV-1 RNA), CD4 counts (helper cells, a type of lymphocyte used to evaluate immunocompetence), p24 antigen (HIV-specific antigen), viral culture, and Nagalase levels remained normal. All patients continued to be free of disease. (Note: anemic HIV patients were excluded from this study. Anemia is common in HIV patients. The effect of GcMAF on anemic HIV patients is thus unknown.)
I personally have followed our patients for 3 years after taking the GcMaf protocols, we confirm that all 6 patients remain HIV free, we continue to follow the results until 10 years have been reached. GcMaf continue’s to prove the most effective protocol for HIV.
How your body makes GcMaf
An illustrated description of the biochemical transformations involved in the synthesis of GcMAF from Vitamin D Binding protein.
How your body makes the GcMAF that activates macrophages and protects you from cancer and viruses
GcMAF and Nagalase are both proteins, so let me start with a brief—and hopefully painless—primer on proteins. You know those birthday present bows made of clusters of curly ribbons? Under a very powerful microscope, proteins look like that. The ribbons are long chains of hundreds of amino acids that make up a protein molecule. Our DNA is programmed to make tens of thousands of different proteins, and what makes them different is the ordering of the amino acids. Each strand (usually there are three or four of them) of curled ribbon in our birthday bow is one of those chains. The curly ribbons are all attached together where the bow is fastened to the present. They may look like a big blob of randomly-placed bands—and in the ribbon, they are. But in a protein, there is a very specific three-dimensional structure, such that even though the curly ribbons look randomly placed, they are, in fact, very precisely positioned—and even slight positional changes will significantly alter the nature of the protein.
Vitamin D-binding protein (DBP) is the precursor protein out of which our immune cells make GcMAF. Up close DBP looks kind of like a small Brillo pad, but the convolutions are not sharp-edged; they’re actually quite soft and sticky. DBP contains 458 amino acids, one of which is very special and quite different from all the others. This is a threonine amino acid, the 420th amino acid in its chain. Attached to this threonine is a group of three sugars. The presence of these sugars defines the purpose of the entire DBP protein molecule. To keep things simple, I am going to name the three sugar molecules after candy bars.
Because Vitamin D Binding Protein comes with sugars attached, we can now refer to it as a glycoprotein. Most of the immune system’s “messenger molecules” are glycoproteins.
Now imagine DBP as this large protein with three sugars (or candy bars) attached. The first is a Hershey’s bar, the second is a Milky Way, and the third is a Snickers. All three are attached to one another, as shown in the diagram, in an upside-down “Y”-shaped configuration.
Vitamin D-Binding Protein (DBP) is the starting point in GcMAF production.
DBP is the protein from which we are going to make GcMAF.
The dashes (–) indicate chemical bonds (pairs of electrons that hold atoms together to form chemicals) that attach the sugars to each other and to the protein.
Making GcMAF from DBP
Now let’s transform our candy bar model of DBP into GcMAF. There are two steps in this process. The first step is to snip off the Milky Way bar. (This is performed by the enzyme beta-galactosidase which is embedded in the outer cell membrane of B-lymphocytes.) You can go ahead and eat it; we won’t need it anymore. If you don’t want it, your body will just recycle it. Intermediate in GcMAF production.
The second step is to snip off the Snickers bar. (This is performed by the enzyme sialidase, which is located in the outer membrane of T-lymphocyte cells.) (You can have that one too, if you want to get on the fast track to diabetes.)
Now we’re left with a huge protein that has just the remaining Hershey’s hanging off of it. Guess what: this is GcMAF.
By snipping off two of the three sugars (first the Milky Way and then the Snickers bar), we have transformed the Vitamin D-Binding Protein into GcMAF.
It’s fully formed and ready to float off, find a macrophage, lock onto its receptor, and then send a powerful message to the entire cell, telling it to stop watching reruns of Desperate Housewives and get to work beating up microbes and killing cancer cells. And, as you know, when GcMAF talks, macros listen.
Candy bar identities revealed
Just for the record (and for you biochemists in the house) my Hershey’s bar is alpha-N-acetylgalactosamine (GalNAc), the Milky Way is D-galactose, and the Snickers bar is sialic acid (also known as N-acetylneuraminic acid).
Now that we have synthesized some GcMAF, we’ll see—in Chapter 9 how Nagalase sabotages it…
The Official Trial
α-N-acetylgalactosaminidase (nagalase) is known to accumulate in the serum of cancer patients, where it mediates the deglycosylation of group-specific component (GC), best known as vitamin D-binding protein (VDBP), which is the precursor of GC protein-derived macrophage-activating factor (GcMAF). Deglycosylated VDBP cannot be converted into GcMAF and decreased GcMAF levels reportedly promote immunodeficiency in individuals bearing advanced neoplasms. The increase in nagalase activity observed in cancer patients is mostly due to the fact that malignant cells release enzymatically active nagalase. Thus, serum nagalase activity reflects not only tumor burden and aggressiveness, but also the clinical progression of the disease. Nowadays, the assessment of serum nagalase activity is proposed as a reliable means to determine the clinical severity of multiple neoplasms.
In serum, nagalase acts as an endo- (but not as an exo-) enzyme, being unable to deglycosylate an N-acetylgalactosamine (GalNAc) residue of GcMAF. Thus, circulating nagalase cannot degrade exogenous GcMAF. This observation suggested that patients with elevated nagalase activity may benefit from the exogenous provision of GcMAF. Alongside, GcMAF was observed to exert multiple anticancer effects in vivo and in vitro, both in experimental and in spontaneous tumor models. Given the impact of GcMAF on macrophages and their central role anticancer immune responses, GcMAF is widely considered as an immunotherapeutic agent.
However, in addition to stimulating tumor-infiltrating macrophages, GcMAF not only directly inhibits the proliferation of various human cancer cells in vitro, but also reverts the malignant phenotype of human breast cancer cells. Moreover, GcMAF reportedly inhibits angiogenesis, thus depriving neoplastic lesions of the oxygen and nutrient supplies that are needed for tumor progression and metastasis. Recently, it has been proposed that the antineoplastic effects of GcMAF are mediated by the vitamin D receptor (VDR), and it was demonstrated that GcMAF stimulates an intracellular signalling pathway impinging on cyclic AMP. This signal transduction cascade could actually be responsible for death of malignant cells exposed to GcMAF. Taken together, these in vitro and in vivo findings lend a rationale to the observation that GcMAF exert dramatic anticancer effects in (at least a fraction of) patients with advanced cancer. Of note, in the aforementioned studies, the anticancer effects of GcMAF were evaluated by measuring serum nagalase activity as a marker of tumor burden and progression.
The biological effects of GcMAF have been documented in a variety of experimental systems and make the subject of more than 50 peer-reviewed papers published during the past 20 y. Because of the solid scientific rationale underlying the compassionate use of GcMAF in advanced cancer patients, hundreds of physicians in all parts of the world have adopted this approach for a variety of indications in which it could prove useful. Here, we present a series of clinical cases exemplifying the results that have been obtained with the administration of GcMAF to patients with diverse types of advanced cancers, with a particular focus on the effects of GcMAF on serum nagalase activity. We are well aware that these cases, because of their heterogeneity and reduced number, can be considered anecdotal. However, a very recent study on the evaluation of clinical practice strongly encourages the re-evaluation of individual cases such as those presented here. Thus, while some studies present large and impressive statistics obtained from large clinical cohorts, others may report a limited number of noteworthy cases, as we do here. According to this novel, authoritative, epistemological approach, “all of these stories become evidence of what works in medicine. Therefore, we believe that the clinical cases reported below point to beneficial effects for the administration of GcMAF to advanced cancer patients, prompting further studies to formally address this possibility.
The mean pre-GcMAF treatment serum nagalase activity documented in our patient cohort was 2.84 ± 0.26 nM/min/mg, with a range of 1.00–5.60 nM/min/mg At the time of second testing (average interval = 112 d), the mean serum nagalase activity in the course of GcMAF treatment was 2.01 ± 0.22 nM/min/mg, with a range of 1.00–3.20 nM/min/mg. The difference between these values was statistically significant (p < 0.05). Of note, no patient of this cohort was initially observed to be within the laboratory reference range for serum nagalase activity (0.90–0.92 nM/min/mg). At the time of final testing (average interval = 263 d), the mean serum nagalase activity of the patient cohort was 1.59 ± 0.17 nM/min/mg, with a range of 0.60–2.80 nM/min/mg. The difference between this value and the serum nagalase activity recorded before the initiation of GcMAF treatment was also statistically significant (p < 0.01).
Amanda Mary Jewell Healing Oracle, Private cancer researcher and holistic practitioner.
You can find us on our website, YouTube and social media!
Love and Light,
Amanda Mary Jewell and The Healing Oracle Team